Intergenic Region News and Research

RSS

New coronavirus variant with E484K mutation detected in Arizona

Arizona joins the ever-growing list of American states harboring a variant of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). A study led by Efrem S. Lim of Arizona State University confirms evidence of the B.1.243.1 with an E484K mutation on the spike protein.

30 Mar 2021

Researchers update automated computation tool for SARS-CoV-2 genome analysis

Researchers updated a previous version of an automated tool to include SARS-CoV-2 genome analysis. Genome analysis using the freely available software could help track the evolution of the virus and promptly identify variants that increase viral transmission or virulence.

22 Jan 2021

A vectored vaccine candidate against SARS-CoV-2

The current pandemic of COVID-19 is caused by the severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2), a betacoronavirus similar to that which caused the SARS-CoV and MERS-CoV earlier. Scientists are pursuing therapeutic drugs and vaccines to counter the relentless spread of the virus, but so far, none has been established to be effective. However, several are in clinical trials in various parts of the world.

2 Jun 2020

Researchers develop new approach to assess effectiveness of Men B vaccine

Researchers at the University of Leicester and Meningococcal Reference Unit have developed a new approach to assess the effectiveness of the Men B vaccine, Bexsero, against different strains that cause meningococcal meningitis and septicaemia.

18 Jun 2018

Genetic variant encoded in NCF1 linked to increased risk for autoimmune diseases, study shows

Investigators at the Medical University of South Carolina report pre-clinical research showing that a genetic variant encoded in neutrophil cystolic factor 1 (NCF1) is associated with increased risk for autoimmune diseases, including systemic lupus erythematosus (SLE), rheumatoid arthritis, and Sjögren's syndrome, in the January 2017 issue of Nature Genetics.

8 Feb 2017

Sigma-Aldrich enters into new gene editing partnership with U-M Medical School's Vector Core

Sigma-Aldrich Corporation announced today it has entered into a new gene editing partnership with the University of Michigan Medical School's Vector Core. Under the partnership, Sigma-Aldrich will provide the Vector Core with Sigma CRISPR technology, experimental design consultation, and dedicated gene editing bioinformaticians.

18 Sep 2014

Intergenic Region News and Research

New coronavirus variant with E484K mutation detected in Arizona

Researchers update automated computation tool for SARS-CoV-2 genome analysis

A vectored vaccine candidate against SARS-CoV-2

Researchers develop new approach to assess effectiveness of Men B vaccine

Genetic variant encoded in NCF1 linked to increased risk for autoimmune diseases, study shows

Sigma-Aldrich enters into new gene editing partnership with U-M Medical School's Vector Core

Susceptible loci identified for bipolar I disorder in Taiwanese

Shared genetic risk for bipolar disorder and BMI

New gene-silencing pathway found in plants

Unlocking the Secrets of Multiple Sclerosis Progression: Brain-Immune Cell Communication

Passing on Polycystic Ovary Syndrome: Health risks for male offspring of women with PCOS

Top-Down Proteomics: Bridging the Genotype-to-Phenotype Gap

Latest News